JY
VTVT icon

Jeff Yass’s vTv Therapeutics VTVT Stock Holding History

Jeff Yass’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302K Buy
+8,023
New +$278K ﹤0.01% 11025
2023
Q4 		– Sell
-507
Closed -$9.69K – 13394
2023
Q3 		$9.69K Sell
507
-1,399
-73% -$34.2K ﹤0.01% 11721
2023
Q2 		$56.4K Buy
1,906
+1,524
+399% +$48.4K ﹤0.01% 11286
2023
Q1 		$12.3K Buy
+382
New +$13K ﹤0.01% 12164
2022
Q4 		– Sell
-556
Closed -$22K – 13798
2022
Q3 		$22K Buy
556
+39
+8% +$1.53K ﹤0.01% 12575
2022
Q2 		$16K Sell
517
-61
-11% -$1.56K ﹤0.01% 12417
2022
Q1 		$17K Buy
+578
New +$17.3K ﹤0.01% 12671
2021
Q3 		– Sell
-1,069
Closed -$97K – 13663
2021
Q2 		$97K Buy
+1,069
New +$108K ﹤0.01% 12112
2020
Q2 		– Sell
-407
Closed -$31K – 11012
2020
Q1 		$31K Buy
+407
New +$39.1K ﹤0.01% 9824
2017
Q1 		– Sell
-307
Closed -$59K – 10068
2016
Q4 		$59K Buy
+307
New +$70.6K ﹤0.01% 9250
2015
Q4 		– Sell
-548
Closed -$143K – 10047
2015
Q3 		$143K Buy
+548
New +$191K ﹤0.01% 8958

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jeff Yass's VTVT Position: Q2 2026 in Review

Jeff Yass opened a new position in vTv Therapeutics (VTVT) in Q2 2026: 8,023 shares worth $302K. The stake represents ﹤0.01% of the portfolio and ranks #11025 among its holdings. This is a return to the name: Jeff Yass previously reported a position in VTVT as recently as Q3 2023.

Jeff Yass first reported a position in VTVT in Q3 2015 and has held it in 11 quarters since. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

  • Jeff Yass held 8,023 shares of vTv Therapeutics worth $302K as of Q2 2026.
  • vTv Therapeutics was a new Jeff Yass position in Q2 2026.
  • vTv Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11025 holding.
  • Jeff Yass first reported a position in vTv Therapeutics in Q3 2015 and has held it in 11 quarters since.
  • 45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.